J&J Did not Warn Levaquin Riskier Than Rivals, Lawyer Argues
J&J Did not Warn Levaquin Riskier Than Rivals, Lawyer Argues
Published October 12, 2011 | Bloomberg Business Week
A Johnson & Johnson unit never warned users of the Levaquin antibiotic that it posed a greater risk of tendon damage than rival medications, a lawyer for two men suing the company said today.
Executives of J&J’s Ortho-McNeil-Janssen Pharmaceutical unit sought to protect sales by omitting information about Levaquin’s “comparative risk” from its warning label, Andy a lawyer for Paul Gaffney and Robert Beare, said in closing arguments in the trial of their lawsuits against the drugmaker.
“They should be held to account for not fully disclosing” that they knew Levaquin generated a higher number of reports of Achilles tendon injuries than competing antibiotics, told a state court jury in Atlantic City, New Jersey, today.
Read More: Levaquin Side Effects Trial
ParkerWaichmanLLP
@ParkerWaichman
parkerwaichman
parkerwaichmanllp